Breaking News:

Article ID: 707682

A detailed analysis of blood samples from Ebola patients is providing clues about the progression of the effects of the virus in patients and potential treatment pathways. The findings point to a critical role for a molecular pathway that relies on the common nutrient choline, as well as the importance of cellular bodies known as microvesicles.

Article ID: 707067

A Phase 1 clinical trial of investigational vaccines intended to protect against Zaire ebolavirus (Ebola) has begun in the United States at Cincinnati Children’s Hospital Medical Center. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

Article ID: 706582

A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts. Scientists at Texas Biomedical Research Institute were part of a nationwide collaborative with scientists at Gladstone Institutes, UC San Francisco and Georgia State University for a study recently published in the journal Cell.

Article ID: 705407

Ebola virus (green) infects human cells much more easily when you remove the protective RBBP6 protein (compare left to right). Researchers have discovered a human protein that helps fight the Ebola virus and could one day lead to an effective therapy against the deadly disease, according to a new study from Northwestern University, Georgia State University, University of California, San Francisco (UCSF) and the Gladstone Institutes published today, Dec.

Article ID: 702339

Texas Biomed researchers – in collaboration with the University of Iowa – are trying to find out how malarial infections impact people exposed to Ebola virus. Both diseases are endemic in that region.

Article ID: 702257

Article ID: 701959

A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.

Article ID: 701256

A new study from the NYU College of Global Public Health and NYU Tandon School of Engineering, published in Nature Digital Medicine, used text message surveys to determine in real time how people used maternal health services during a recent Ebola outbreak and measured a drop in hospital-based births during the outbreak.

Article ID: 700447

Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.

Article ID: 699544

Geneticist Jason Ladner talks about the study, which underscores the need for focused prevention efforts among survivors and better capacity to detect new cases of the deadly virus.